26577-57-1

Upstream product

• 110-91-8 morpholine 
• 39910-98-0 4-morpholinoacetophenone 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 39911-99-4 ethyl 4-(morpholin-4-yl)phenylacetate 

Downstream Products

• 1450907-82-0 C₂₁H₂₁N₃O 
• 1450907-83-1 C₂₅H₃₁NO₅ 
• 1450907-93-3 C₂₁H₃₃N₃O₅ 
• 111601-67-3 methyl 4-morpholinophenylacetate 
• 111601-71-9 4-morpholinophenylacetic acid N-oxide 
• 111601-69-5 picrate of methyl 4-morpholinophenylacetate N-oxide 
• 111601-70-8 hydrochloride of morpholinophenylacetic acid N-oxide 
• 1027325-14-9 N-[5-(2,4-Dioxo-thiazolidin-5-ylmethyl)-2-hydroxy-phenyl]-2-(4-morpholin-4-yl-phenyl)-acetamide 

Relevant academic research and scientific papers

USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS

A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compo

T-TYPE CALCIUM CHANNEL BLOCKER

To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker. wherein A represents a phenyl which may have a substituent, a 4-membered to 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, wherein the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to a nitrogen atom of the adjacent cyclic amino by means of a carbon atom constituting these rings; B represents a phenyl which may have a substituent, a 5-membered or 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, wherein the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to the adjacent cyclopropyl ring by means of a carbon atom constituting these rings; R1 and R2, which may be identical or different, each represent a hydrogen atom, a halogen atom, or the like; R3 represents a hydrogen atom, a halogen atom, or the like; n and m, which may be identical or different, each represent 0 or 1; and p represents 1 or 2.

Decarboxylative allylation of amino alkanoic acids and esters via dual catalysis

A combination of photoredox and palladium catalysis has been employed to facilitate the room temperature decarboxylative allylation of recalcitrant amino and phenylacetic allyl esters. This operationally simple process produces CO2as the only b

Visible light-mediated oxidative decarboxylation of arylacetic acids into benzyl radicals: Addition to electron-deficient alkenes by using photoredox catalysts

Reactions of arylacetic acids bearing an amino group at the para-position in the benzene ring with alkenes in the presence of a catalytic amount of transition metal polypyridyl complexes as photocatalysts under visible light illumination proceed smoothly to give the corresponding benzylated products via oxidative decarboxylation in good to high yields.

PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

Para-aryl or heterocyclic substituted phenyl glucokinase activators

Para-aryl or heteroaryl substituted phenyl amides which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.